MONOCLONAL ANTIBODY ANTAGONIZING AND INHIBITING BINDING BETWEEN HUMAN PD-1 ANTIGEN AND LIGAND THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

• Main Authors: HU, Hongqun, ZHOU, Qunmin, CHEN, Zui, XU, Yiqing, CAI, Mingwen, LUO, Shiping, FAN, Jinling, SONG, Xiaoqi
• Format: Patent
• Language: English; French; German
• Published: 22.11.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

Disclosed in the present invention is a monoclonal antibody or a derivative thereof which can antagonize and inhibit the binding of human PD-1 antigen to its ligand: the amino acid sequences of CDR1, CDR 2 and CDR 3 in the light chain variable region of the antibody are shown in SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, while the amino acid sequences of CDR 1, CDR 2 and CDR 3 in the heavy chain variable region are shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. Further disclosed are a humanization preparation process for the antibody and the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody. The antibody or a derivative thereof can be used as a component of pharmaceutical composition or an appropriate pharmaceutic preparation either alone or in combination with other treatments such as chemotherapeutics to cure colon cancer and other solid tumors.